<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04609852</url>
  </required_header>
  <id_info>
    <org_study_id>E8001-J081-001</org_study_id>
    <nct_id>NCT04609852</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety and Tolerability of E8001 in Healthy Male Participants</brief_title>
  <official_title>A Randomized, Single-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of E8001 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK)&#xD;
      of E8001 of single ascending dose intravenous infusions in healthy male participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 28, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Screening up to Day 180 (approximately 292 days)</time_frame>
    <description>Safety assessments will consist of monitoring and recording all adverse events (AEs) and SAEs; regular monitoring of clinical laboratory parameters; and periodic measurement of vital signs and 12-lead electrocardiogram (ECG), body weight and physical examinations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax: Maximum Observed Plasma Concentration for E8001</measure>
    <time_frame>Day 1: 0-168 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for E8001</measure>
    <time_frame>Day 1: 0-168 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-t): Area Under the Concentration-time Curve From Zero (Pre-dose) to Time of Last Quantifiable Concentration for E8001</measure>
    <time_frame>Day 1: 0-168 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>T1/2: Terminal Elimination Phase Half-life for E8001</measure>
    <time_frame>Day 1: 0-168 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CL: Total Clearance for E8001</measure>
    <time_frame>Day 1: 0-168 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vss: Volume of Distribution at Steady State for E8001</measure>
    <time_frame>Day 1: 0-168 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Corrected QT (QTc) Interval</measure>
    <time_frame>Day 1: 0-24 hours</time_frame>
    <description>To assess the effect of E8001 on ventricular repolarization by assessing the QTc interval corrected by the Fridericia formula (QTcF).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Cohort 1: E8001 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive specified dose of E8001 or placebo (isotonic sodium chloride solution), infusion, intravenously, once on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: E8001 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive specified dose of E8001 or placebo (isotonic sodium chloride solution), infusion, intravenously, once on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: E8001 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive specified dose of E8001 or placebo (isotonic sodium chloride solution), infusion, intravenously, once on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: E8001 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive specified dose of E8001 or placebo (isotonic sodium chloride solution), infusion, intravenously, once on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E8001</intervention_name>
    <description>Intravenous infusion.</description>
    <arm_group_label>Cohort 1: E8001 or Placebo</arm_group_label>
    <arm_group_label>Cohort 2: E8001 or Placebo</arm_group_label>
    <arm_group_label>Cohort 3: E8001 or Placebo</arm_group_label>
    <arm_group_label>Cohort 4: E8001 or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous infusion.</description>
    <arm_group_label>Cohort 1: E8001 or Placebo</arm_group_label>
    <arm_group_label>Cohort 2: E8001 or Placebo</arm_group_label>
    <arm_group_label>Cohort 3: E8001 or Placebo</arm_group_label>
    <arm_group_label>Cohort 4: E8001 or Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Non-smoking, age greater than or equal to (&gt;=) 20 years and less than or equal to (&lt;=)&#xD;
             55 years old adult male at the time of informed consent. To be considered non-smokers,&#xD;
             participants must have discontinued smoking for at least 4 weeks before dosing&#xD;
&#xD;
          2. Body mass index (BMI) &gt;=18.5 and less than (&lt;) 25.0 kilogram per square meter (kg/mË„2)&#xD;
             at Screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Males who have not had a successful vasectomy (confirmed azoospermia) or they and&#xD;
             their female partners do not meet the criteria (that is, not of childbearing potential&#xD;
             or practicing highly effective contraception throughout the study period or for 5&#xD;
             times the half-life of the study drug plus 90 days after study drug discontinuation).&#xD;
             No sperm donation is allowed during the study period and for 5 times the half-life of&#xD;
             the study drug plus 90 days after study drug discontinuation&#xD;
&#xD;
          2. Clinically significant illness that requires medical treatment within 8 weeks or a&#xD;
             clinically significant infection that requires medical treatment within 4 weeks of&#xD;
             dosing&#xD;
&#xD;
          3. History of meningococcal infection or pneumococcal infection&#xD;
&#xD;
          4. Evidence of disease that may influence the outcome of the study within 4 weeks before&#xD;
             dosing; example- psychiatric disorders and disorders of the gastrointestinal tract,&#xD;
             liver, kidney, respiratory system, endocrine system, hematological system,&#xD;
             neurological system, or cardiovascular system, or participants who have a congenital&#xD;
             abnormality in metabolism&#xD;
&#xD;
          5. Any history of gastrointestinal surgery that may affect PK profiles of E8001, example-&#xD;
             hepatectomy, nephrectomy, and digestive organ resection at Screening&#xD;
&#xD;
          6. Any clinically abnormal symptom or organ impairment found by medical history at&#xD;
             Screening, and physical examinations, vital signs, ECG finding, or laboratory test&#xD;
             results that require medical treatment at Screening or Baseline&#xD;
&#xD;
          7. History of prolonged QT/QTc interval&#xD;
&#xD;
          8. History of left bundle branch block (LBBB)&#xD;
&#xD;
          9. History of myocardial infarction (MI) or active ischemic heart disease (IHD)&#xD;
&#xD;
         10. History of clinically significant arrhythmia or uncontrolled arrhythmia&#xD;
&#xD;
         11. Active viral hepatitis (A, B or C) and syphilis as demonstrated by positive serology&#xD;
             at Screening&#xD;
&#xD;
         12. History of drug or alcohol dependency or abuse, or those who have a positive drug test&#xD;
             at Screening or Baseline&#xD;
&#xD;
         13. Liver function test with following values at Screening or Baseline:&#xD;
&#xD;
               1. aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline&#xD;
                  phosphatase (ALP), or gamma glutamyl transpeptidase (GGT): greater than (&gt;) upper&#xD;
                  limit of normal (ULN)&#xD;
&#xD;
               2. direct bilirubin or total bilirubin: &gt;1.5*ULN&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Inquiry Service</last_name>
    <email>eisai-chiken_hotline@hhc.eisai.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Minato-ku</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 26, 2020</study_first_submitted>
  <study_first_submitted_qc>October 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2020</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy Participants</keyword>
  <keyword>E8001</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Eisai's data sharing commitment and further information on how to request data can be found on our website http://eisaiclinicaltrials.com/.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

